What is CSWYY P/E ratio?

China Shineway Pharmaceutical Group Limited's P/E ratio is 5.70. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is CSWYY return on equity (ROE)?

China Shineway Pharmaceutical Group Limited's return on equity (ROE) is 11.97%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is China Shineway Pharmaceutical Group Limited's market cap?

China Shineway Pharmaceutical Group Limited has a market capitalization of $36.35M.

OTC · Drug Manufacturers - Specialty & Generic

China Shineway Pharmaceutical Group Limited (CSWYY) Stock

Q: What is China Shineway Pharmaceutical Group Limited (CSWYY) stock price today?

China Shineway Pharmaceutical Group Limited (CSWYY) is currently trading at $19.25, up 0% today.

$19.25 +0.00% OTC: CSWYY Healthcare

Valuation

Metric	Value
Price	$19.25
Market Cap	$36.35M
P/E Ratio	5.70
P/B Ratio	0.67
P/S Ratio	1.72
EPS (TTM)	$3.38
52-Week High	$22.54
52-Week Low	$19.25
Dividend Yield	12.16%

Financials & Margins

Metric	Value
ROE	11.97%
ROA	8.81%
ROCE	8.25%
Gross Margin	72.28%
Operating Margin	21.75%
Net Margin	30.30%
Debt/Equity	0.04
Current Ratio	3.71

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$3.2B	$4.0B	$4.5B	$3.8B	$3.0B
Operating Profit	$527.0M	$726.0M	$976.0M	$843.0M	$663.0M
Net Profit	$557.0M	$723.0M	$970.0M	$840.0M	$924.0M
EPS	$296.00	$384.00	$513.40	$444.00	$489.40
Op Margin	16.6%	18.1%	21.6%	22.3%	21.8%

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$7.2B	$8.2B	$9.6B	$10.0B	$10.8B
Total Liabilities	$1.3B	$1.8B	$2.5B	$2.6B	$2.7B
Cash	$4.2B	$5.0B	$5.9B	$6.1B	$7.2B
Borrowings	$15.0M	$7.0M	$301.0M	$347.0M	$335.0M

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$703.0M	$1.1B	$933.0M	$963.0M	$1.2B
Investing Cash Flow	$301.0M	$-175.0M	$-194.0M	$-412.0M	$24.0M
Financing Cash Flow	$-10.0M	$-8.0M	$-9.0M	$-15.0M	$-15.0M
Net Cash Flow	$263.0M	$821.0M	$863.0M	$251.0M	$1.0B
Free Cash Flow	$610.0M	$980.0M	$788.0M	$823.0M	$974.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.45
EV / EBITDA	-1.78
FCF Yield	19.72%
Quick Ratio	3.43
Interest Coverage	110.50
Return 1Y	8.63%
Return 3Y	27.29%
Return 5Y	—

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ACOGFAlpha Cognition Inc.	$5.73	—	-38.17	$35.66M	0.00%
BFFTFBiofrontera AG	$0.33	-95.24%	-0.97	$19.35M	0.00%
CHBRFChill Brands Group PLC	$0.05	+48.84%	-5.00	$24.45M	0.00%
DMTTFSmall Pharma Inc.	$0.11	-9.69%	-2.20	$37.51M	0.00%
ENZBEnzo Biochem, Inc.	$0.70	-0.16%	-8.80	$36.59M	0.00%

About China Shineway Pharmaceutical Group Limited

As an investment holding company, China Shineway Pharmaceutical Group Limited primarily focuses on the research, development, production, and commercialization of traditional Chinese medicines across mainland China and Hong Kong. Its product portfolio encompasses contemporary Chinese medicines delivered as soft capsules, granules, and injectable solutions. Additionally, it provides specialized TCM Formula Granules, addressing a broad spectrum of medical conditions such as cardiovascular and cerebrovascular issues, viral infections, orthopedic complaints, pediatric ailments, gynecological disorders, and gastrointestinal problems. Beyond pharmaceuticals, the group also engages in the trading of agricultural commodities. Established in 2004, China Shineway Pharmaceutical Group Limited maintains its corporate headquarters in Shijiazhuang, within the People's Republic of China. The company operates as a subsidiary under the umbrella of Forway Investment Limited.

China Shineway Pharmaceutical Group Limited is headquartered in CN.

China Shineway Pharmaceutical Group Limited (CSWYY) stock trades at $19.25 with a market capitalization of $36.35M. The stock is valued at a price-to-earnings (P/E) ratio of 5.70, price-to-book of 0.67, price-to-sales of 1.72. Over the past 52 weeks the stock has ranged between $19.25 and $22.54, and currently trades 14.6% below its 52-week high. It pays a dividend yielding 12.16%.

On profitability, China Shineway Pharmaceutical Group Limited generates a return on equity (ROE) of 11.97%, return on capital employed of 8.25%, an operating margin of 21.75%, a net profit margin of 30.30%.

Official website: www.shineway.com.hk